Arvinas

Did you know that our founder, Dr. Craig Crews, co-authored the first paper on targeted protein degradation over 20 years ago? Since then, we've been at the forefront of advancing this groundbreaking technology. To celebrate our 11-year journey and the incredible progress we've made, we're thrilled to launch the #ScienceOfPROTAC series. We invite you to join us in exploring the fascinating world of #PROTAC protein degraders. Got any burning questions about PROTAC protein degraders? Drop them in the comments below, and let's dive into the science together! #TargetedProteinDegradation #Innovation #biotech #science #thoughtleadership

At #Arvinas, we celebrate the spirit of freedom and innovation that drives our mission to improve the lives of patients suffering from debilitating and life-threatening diseases. On this #4thofJuly, we honor the courage and determination that define our nation's history and our commitment to making a positive impact on global health. Wishing everyone a safe and joyous celebration!

Thrilled to highlight the most read article from the Journal of Medicinal Chemistry in 2023, published by the American Chemical Society was authored by our own Keith Hornberger and Erika Vieira Araujo! Explore the full article below. #TeamArvinas #MedicinalChemistry #DrugDiscovery #PharmaceuticalResearch

#News: Today we appointed Andrew Saik as Chief Financial Officer and Treasurer. Read our full press release here: https://rb.gy/9ajwk1

Meet Yuanyuan Zhang, a Principal Research Investigator in Clinical Pharmacology at #Arvinas! She plays a crucial role in the Pharmacokinetic analysis of our clinical trials to optimize dosing for safety and efficacy.   Beyond her professional achievements, she enjoys spending time watching her son play basketball and indulging in her love for reading and movies. One of her all-time favorites is "Gone with the Wind." She also dreams of relaxing on a tropical beach, soaking up the sun and the serene ocean views.    Being a part of #TeamArvinas is not just a job; it’s a shared mission.   Learn more about other members of the team here: https://rb.gy/lhp36x     #TPD #WorkAtArvinas #EmployeeExperience #CompanyCulture 

#News: Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 Read the full press release here: https://rb.gy/gpk4av

Today #TeamArvinas honors and reflects on #Juneteenth, and the significant contributions Black Americans have made in the U.S. One of Arvinas’ leadership guiding principles is to “Encourage a Culture of Belonging and Purpose.” This is important to our success because it ensures unique voices and perspectives are heard and considered in decision-making processes. By celebrating diversity and honoring this historical day, we hope to inspire confidence in all individuals to be able to show up fully and authentically at work. #FreedomDay #Diversity #Inclusion #CompanyCulture  

#NEWS: Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer. Read the full press release here: https://rb.gy/tco69m

We invented PROTAC® protein degraders and #TeamArvinas is inspired daily by the potential for our science to drive much-needed advances in drug discovery. Learn more about our approach and our PROTAC® Discovery Engine: https://bit.ly/3ynyVkl     #biotech #science #thoughtleadership  

During #MensHealthWeek, we are shedding light on the men living with a #BreastCancer diagnosis. The Centers for Disease Control and Prevention estimates nearly 1 out of every 100 breast cancer diagnoses in the United States are in men, often those with a strong family history of the disease. At #TeamArvinas, we recognize that the diagnosis of breast cancer can be a difficult time to navigate for all patient populations. Learn more about the resources available for patients with breast cancer: https://lnkd.in/gMSiPedg